<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of psoriatic arthritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of psoriatic arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of psoriatic arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dafna D Gladman, MD, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ana-Maria Orbai, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joachim Sieper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Effective treatment of psoriatic arthritis (PsA) requires coordinated intervention to address the major domains of the disease, including peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement.</p><p>The severity of involvement in each domain may range from mild to severe; some patients experience debilitating disease in one or more domains. Each of these domains must be evaluated independently in order to develop a comprehensive treatment regimen.</p><p>The care of a patient with PsA also requires evaluation of comorbid conditions, many of which negatively impact therapeutic response.</p><p>The treatment of axial arthritis, enthesitis, and dactylitis is discussed in this topic review. The treatment of peripheral arthritis, psoriatic skin and nail involvement, the clinical manifestations and diagnosis of PsA, the pathogenesis of PsA, and the safety of specific drugs during pregnancy and lactation are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96391.html" rel="external">"Nail psoriasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7791.html" rel="external">"Pathogenesis of psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p></p><p class="headingAnchor" id="H53776344"><span class="h1">PRETREATMENT RECOMMENDATIONS</span><span class="headingEndMark"> — </span>The approach to treatment includes therapy for both musculoskeletal disease and disease of the skin and nails. The goal of therapy is to control inflammation and prevent discomfort, joint damage, and disability [<a href="#rid1">1,2</a>]. Psoriatic arthritis (PsA) often affects multiple disease domains simultaneously.</p><p class="headingAnchor" id="H385842751"><span class="h2">Disease domains and treatment selection</span><span class="headingEndMark"> — </span>Treatment is guided initially by an assessment of disease impact on each of the following domains:</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Axial arthritis</p><p class="bulletIndent1"><span class="glyph">●</span>Dactylitis</p><p class="bulletIndent1"><span class="glyph">●</span>Enthesitis</p><p class="bulletIndent1"><span class="glyph">●</span>Skin</p><p class="bulletIndent1"><span class="glyph">●</span>Nails</p><p></p><p>For patients with multidomain involvement, we try to select a therapy that treats all the domains. If this is not possible, we focus on the domain that is most troubling to the patient. For example, we would suggest a tumor necrosis factor (TNF), interleukin 17 (IL-17), or Janus kinase (JAK) inhibitor in patients presenting with both peripheral and axial disease  (<a class="graphic graphic_figure graphicRef142062" href="/z/d/graphic/142062.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a>.)</p><p class="headingAnchor" id="H405962097"><span class="h2">Importance of early treatment</span><span class="headingEndMark"> — </span>Patients benefit from early intervention [<a href="#rid3">3,4</a>]. One study of 283 PsA patients demonstrated that those who saw a rheumatologist within six months of symptom onset had better radiographic and functional outcomes than patients seen later [<a href="#rid3">3</a>]. Similarly, another study found that patients who presented to a clinic specializing in the care of PsA within two years of diagnosis had less joint damage than those who presented later [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3941473153"><span class="h2">Treat-to-target approach</span><span class="headingEndMark"> — </span>Therapies should be selected using a treat-to-target approach, in which treatments are adjusted every three months to achieve remission or low disease activity [<a href="#rid5">5-7</a>]. Application of a treat-to-target strategy to the management of PsA is a principle recommendation of an international task force for PsA and spondyloarthritis [<a href="#rid6">6,7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of target</strong> – The choice of the target should be tailored with the patient; low disease activity may be a more appropriate target in patients with longstanding disease or multiple comorbidities, in whom remission may be particularly difficult to achieve.</p><p></p><p class="bulletIndent1">The choice of the target also depends on which disease domains are most relevant to the patient. For example, some patients are most concerned about controlling arthritis, while others are more focused on psoriasis even in the presence of active joint inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shared decision-making</strong> – Treatment choices should reflect the patient’s goals and preferences. For example, shared decision-making should be employed in selecting the treatment target. Patients may also have preferences regarding certain medications because of the route of administration and/or potential side effects. Shared decision-making can result in better adherence, improved patient outcomes, and reduced disease progression [<a href="#rid8">8-11</a>].</p><p></p><p class="bulletIndent1">Shared decision-making requires that patients are educated regarding the nature of their condition and the effect of stress on their disease, as well as the importance of managing the cardiovascular risk associated with the disease and other comorbidities. (See  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis", section on 'Comorbidities'</a> and  <a class="medical medical_review" href="/z/d/html/15278.html" rel="external">"Comorbid disease in psoriasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multispecialty coordination</strong> – Patients benefit from evaluation and treatment early in the disease by clinicians with expertise in the care of patients with rheumatologic conditions [<a href="#rid3">3,4</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1">Treatment should be coordinated between a rheumatologist, primary care clinician, and relevant specialists (eg, dermatologist). Patients should be referred as needed for prevention and medical management of comorbid conditions. Many patients may not have a primary care clinician who can coordinate the patient’s care, in which case this role may need to be assumed by the rheumatologist.</p><p></p><p class="headingAnchor" id="H2226559053"><span class="h2">Comorbidities</span><span class="headingEndMark"> — </span>Comorbidities (eg, diabetes, metabolic syndrome, fatty liver, coronary artery disease, depression, hyperuricemia) are prevalent in PsA and should be identified because they can affect overall health and treatment selection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk factors</strong> – All patients should be screened for cardiovascular risk factors (eg, lipids, blood pressure, and smoking history).</p><p></p><p class="bulletIndent1">In patients with elevated cardiovascular risk, JAK inhibitors should be prescribed with great caution following a detailed discussion with the patient regarding risks and benefits of these drugs based on data in rheumatoid arthritis populations [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders", section on 'Cardiovascular'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – Weight loss improves PsA outcomes in patients with obesity [<a href="#rid13">13,14</a>]. Patients with an elevated body mass index (BMI) should undergo weight-loss counseling and evaluation for nonalcoholic fatty liver disease and diabetes.</p><p></p><p class="bulletIndent1">When relevant, patients should be referred for physical and occupational therapy, encouraged to exercise, referred as needed for orthotics, and educated about joint protection. (See  <a class="medical medical_review" href="/z/d/html/120020.html" rel="external">"Exercise prescription and guidance for adults", section on 'Prescribing an exercise program'</a> and  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Approach to therapy'</a>.)</p><p></p><p class="bulletIndent1">In patients with obesity, intravenous biologic agents (eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>) may be preferred over subcutaneous biologic agents, which may have variable absorption. In patients with diabetes, agents with a lower risk of infection such as <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, IL-23 or IL-12/23 inhibitors may be preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety and depression</strong> – Many patients suffer from anxiety and depression, disorders that may result in medication nonadherence and avoidance of systemic therapies.</p><p></p><p class="bulletIndent1">In patients with severe anxiety and depression, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> should be avoided due to a potential association with suicidality.</p><p></p><p class="headingAnchor" id="H1132603329"><span class="h1">PERIPHERAL ARTHRITIS</span><span class="headingEndMark"> — </span>The management of the peripheral arthritis of psoriatic arthritis (PsA) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a>.)</p><p class="headingAnchor" id="H133947872"><span class="h1">AXIAL DISEASE</span></p><p class="headingAnchor" id="H133947879"><span class="h2">Mild axial symptoms</span><span class="headingEndMark"> — </span>In patients with mild symptoms of axial disease, which includes patients with inflammatory back pain that does not interfere with function, we suggest the use of nonsteroidal antiinflammatory drugs (NSAIDs) in antiinflammatory dose regimens, which may be at the higher end of the dosing range (eg, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> 375 to 500 mg twice daily, <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> 100 to 150 mg daily in divided doses, <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> 200 mg twice daily)  (<a class="graphic graphic_table graphicRef70067" href="/z/d/graphic/70067.html" rel="external">table 1</a>).</p><p>NSAIDs can lessen pain and stiffness in spondylitis, although support for their use for axial manifestations of psoriatic arthritis (PsA) is based upon their demonstrated benefit in patients with ankylosing spondylitis, expert opinion, and clinical experience [<a href="#rid1">1,2,15-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Initial drug therapy with NSAIDs'</a>.)</p><p class="headingAnchor" id="H133947886"><span class="h2">Moderate to severe axial disease</span><span class="headingEndMark"> — </span>In patients with axial symptoms that do not respond adequately to treatment with NSAIDs, such as those with prolonged morning stiffness and severe pain interfering with function, we recommend a tumor necrosis factor (TNF) or interleukin 17 (IL-17) inhibitor rather than a traditional nonbiologic disease-modifying antirheumatic drug (DMARD), as the latter have been shown to be ineffective for axial spondyloarthritis [<a href="#rid18">18-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'TNF inhibitors'</a>.)</p><p>Choosing between TNF versus IL-17 inhibition may be influenced by comorbid conditions. For example, IL-17 inhibitors are more effective for severe psoriasis but not for inflammatory bowel disease or iritis. In the absence of these considerations, treatment selection is based on patient, physician, and payor preference. Many clinicians reserve these agents for patients who do not have an adequate treatment response to at least one TNF inhibitor. (See <a class="local">'Axial disease resistant to initial tumor necrosis factor inhibitor'</a> below.)</p><p>Use of the TNF inhibitors for axial disease in patients with PsA is supported by evidence of benefit for axial spondyloarthritis in trials involving patients with ankylosing spondylitis [<a href="#rid17">17</a>] as well as by expert opinion [<a href="#rid15">15,21,22</a>] (see  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'TNF inhibitors'</a>). Available TNF inhibitors and recommendations for dosing are provided in the table  (<a class="graphic graphic_table graphicRef143868" href="/z/d/graphic/143868.html" rel="external">table 2</a>)<em>.</em></p><p class="headingAnchor" id="H49302270"><span class="h2">Axial disease resistant to initial tumor necrosis factor inhibitor</span><span class="headingEndMark"> — </span>In patients with axial symptoms that do not respond adequately to initial therapy with a TNF inhibitor, we switch to a second TNF inhibitor  (<a class="graphic graphic_table graphicRef143868" href="/z/d/graphic/143868.html" rel="external">table 2</a>), IL-17 inhibitor (ie, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> or <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>), or Janus kinase (JAK) inhibitor.</p><p>Use of IL-17 inhibitors for axial disease has been supported in several clinical trials:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> – In the MAXIMIZE trial, secukinumab (150 or 300 mg weekly for four weeks, then monthly thereafter) was more effective than placebo for the treatment of PsA-associated axial disease at week 12 (ASAS20 64 versus 31 percent) with a safety profile that paralleled that observed in patients with PsA with peripheral joint involvement  (<a class="graphic graphic_table graphicRef142897" href="/z/d/graphic/142897.html" rel="external">table 3</a>) [<a href="#rid23">23</a>]. Additionally, two ankylosing spondylitis trials (MEASURE 1 and 2) have shown a clear benefit of secukinumab compared with placebo, providing indirect evidence of benefit for this agent for the axial disease of PsA [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Secukinumab'</a>.)</p><p></p><p class="bulletIndent1">An intravenous formulation of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> is also available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a> – We use ixekizumab in axial PsA based on data from axial spondyloarthritis. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Ixekizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>JAK inhibitors</strong> – JAK inhibitors are recommended based on their efficacy for the treatment of ankylosing spondylitis. Two clinical trials for <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> [<a href="#rid25">25,26</a>] and two phase 3 clinical trials for <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> [<a href="#rid27">27-29</a>] have demonstrated significant improvements in magnetic resonance imaging (MRI) of the spine and sacroiliac joints compared with placebo in patients with ankylosing spondylitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> – IL-12/23 inhibitors (eg, ustekinumab) are not currently recommended for axial disease given their lack of efficacy for the treatment of axial spondyloarthritis [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Biologic and other agents effective in other diseases but not axial SpA'</a>.)</p><p></p><p class="bulletIndent1">However, a post hoc analysis of a clinical trial suggest that it may be effective for axial spondyloarthritis [<a href="#rid31">31</a>]. A randomized clinical trial designed specifically to examine the efficacy of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> for axial PsA is underway [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H2698880950"><span class="h2">Axial disease resistant to multiple agents</span><span class="headingEndMark"> — </span>For patients who do not have an adequate response (or have a contraindication to) TNF inhibition and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, we transition the patient to <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>. A case series reported clinically meaningful improvement in PsA axial disease outcomes (improvement of 1.1 or more points in Ankylosing Spondylitis Disease Activity Score [ASDAS]) in half of the patients (8 of 16) upon switching from secukinumab to ixekizumab [<a href="#rid33">33</a>]. This is consistent with our clinical experience with switching to a second IL-17 inhibitor.</p><p>For patient who do not have an adequate response (or have a contraindication to) JAK inhibition and multiple TNF and IL-17 inhibitors, an IL-23 inhibitor (ie, <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>) may be considered. However, the most recent Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations found that evidence was conflicting or insufficient to make a recommendation for this therapeutic class specifically in axial PsA [<a href="#rid18">18,20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">Guselkumab</a> – In a post hoc analysis of PsA patients enrolled in two clinical trials (DISCOVER 1 and 2) who had axial involvement, patients treated with guselkumab 100 mg every eight weeks experienced improvements in spinal pain, as measured by a 10-point visual analog scale (-2.7 versus -1.2). Patients treated with guselkumab 100 mg every four weeks experienced similar improvements in spinal pain (-2.5 versus -1.2) [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis", section on 'Guselkumab'</a>.)</p><p></p><p class="headingAnchor" id="H133948046"><span class="h1">ENTHESITIS AND DACTYLITIS</span><span class="headingEndMark"> — </span>Enthesitis and dactylitis often benefit from the therapies being used to treat other clinical manifestations [<a href="#rid35">35,36</a>].</p><p class="headingAnchor" id="H48734891"><span class="h2">Enthesitis</span><span class="headingEndMark"> — </span>In patients with enthesitis, which often affects the plantar fascia and the Achilles tendon insertion, we suggest initial treatment with nonsteroidal antiinflammatory drugs (NSAIDs)  (<a class="graphic graphic_table graphicRef70067" href="/z/d/graphic/70067.html" rel="external">table 1</a>).</p><p>Local measures, including physical therapy and local glucocorticoid injection into the entheses, are sometimes beneficial, but their use has not been systematically evaluated in patients with psoriatic arthritis (PsA). We avoid glucocorticoid injection into the Achilles insertion, which has been associated with tendon rupture. Glucocorticoid injections into the plantar fascia and epicondyles are better tolerated.</p><p>In patients with functional limitation due to enthesitis, in whom NSAIDs, local measures, and treatments for other manifestations are insufficient to control the inflammation, we suggest either a biologic agent (eg, a tumor necrosis factor [TNF] inhibitor) or conventional nonbiologic disease-modifying antirheumatic drugs (DMARDs) [<a href="#rid37">37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Most of the biologic DMARDs (TNF, interleukin 17 [IL-17], IL-12/23, IL-23 inhibitors) and Janus kinase (JAK) inhibitors used for peripheral arthritis have also been reported to be effective for enthesitis [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a head-to-head trial of <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> versus <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> for PsA, enthesitis resolved by week 24 in over half of patients taking oral upadacitinib (either 15 or 30 mg daily), 47 percent of patients taking subcutaneous adalimumab (40 mg every other week), and 32 percent of patients taking placebo [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of 403 patients with enthesitis from PsA, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> (80 mg subcutaneous every four weeks) resulted in a significantly higher resolution of enthesitis than placebo (39 versus 21 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> may be effective for the treatment of enthesitis. The SEAM-PsA clinical trial compared <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> and combination etanercept and methotrexate treatments with methotrexate alone in active PsA and found no difference in enthesitis change scores or enthesitis resolution among the treatment arms [<a href="#rid41">41</a>]. However, a placebo group was not included in this trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">Apremilast</a> has also been shown to improve enthesitis and may be more effective than <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for the treatment of enthesitis [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H2446732216"><span class="h2">Dactylitis</span><span class="headingEndMark"> — </span>Dactylitis generally occurs in association with disease activity in other domains (eg, peripheral joint disease). In such cases, treatments are generally selected based on these other domains, rather than the dactylitis alone.</p><p>When present in isolation, we treat mild dactylitis (ie, affecting one or two digits and not interfering with function) with NSAIDs or conventional DMARDs (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 15 to 25 mg once weekly). We treat moderate to severe dactylitis (ie, affecting multiple digits or interfering with function) with biologic DMARDs or JAK inhibitors.</p><p>We treat dactylitis refractory to systemic therapies with glucocorticoid injection (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 10 mg). Ultrasound guidance may be useful for clinicians who are not experienced in the delivery of glucocorticoids into the intraarticular space of the small joints or inside the tendon sheaths that are involved by dactylitis. Flexor or extensor tendons or their insertions should never be directly injected due to risk of injury or rupture and loss of tendon function.</p><p>In a study of 44 patients with PsA presenting with dactylitis (who had not previously been treated with either <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or biologic DMARDs), treatment with <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> and methotrexate was superior to methotrexate alone when measured either with MRI or clinical assessment at 24 weeks [<a href="#rid43">43</a>].</p><p>Other studies of biologic DMARDs and JAK inhibitors have reported improvements in dactylitis as secondary outcomes [<a href="#rid44">44</a>]. However, less than half of patients in these trials had dactylitis. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>In the SEAM-PsA trial, efficacy for dactylitis (measured as change in the Leeds dactylitis index at 24 weeks, as well as percentage with complete resolution of dactylitis) was similar among patients treated with subcutaneous <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> (50 mg weekly) versus oral <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (20 mg weekly) [<a href="#rid41">41</a>]. Combining methotrexate and etanercept did not improve the dactylitis response rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a head-to-head trial of <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> versus <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> for PsA, dactylitis resolved by week 24 in over 75 percent of patients taking oral upadacitinib (either 15 or 30 mg daily), 74 percent of patients taking subcutaneous adalimumab (40 mg every other week), and 40 percent of patients taking placebo [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 155 patients with dactylitis from PsA, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> (80 mg subcutaneous every four weeks) resulted in a significantly higher resolution of dactylitis than placebo (78 versus 24 percent) [<a href="#rid40">40</a>].</p><p></p><p class="headingAnchor" id="H2055578428"><span class="h1">LIMITED ROLE OF GLUCOCORTICOIDS</span><span class="headingEndMark"> — </span>Use of oral glucocorticoids in patients with psoriatic arthritis (PsA) should generally be avoided due to the risk of psoriatic flare. However, oral glucocorticoids are prescribed for rare patients with severe flares unresponsive to nonsteroidal antiinflammatory drugs (NSAIDs) and conventional or biologic disease-modifying antirheumatic drugs (DMARDs). Glucocorticoids are sometimes prescribed for other conditions, in which case there needs to be collaborative management.</p><p>We suggest tapering glucocorticoids slowly (eg, every three days); rapid reductions in glucocorticoid dose are associated with an increased risk of erythroderma or pustular psoriasis. A systematic review of studies including patients with PsA or psoriasis indicated that glucocorticoids (in the absence of taper) are associated with a low risk of flare affecting the joints [<a href="#rid45">45</a>]. In patients requiring chronic therapy with systemic glucocorticoids, the lowest dose necessary (eg, less than 5 mg daily of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) should be employed.</p><p>Injection of glucocorticoids into tendon insertions should not be performed because of a risk of tendon rupture, and data supporting efficacy of this approach are not available.</p><p>Intraarticular glucocorticoids are sometimes used, and care should be taken in patients who require such injections to avoid injection through psoriatic plaques. We use intraarticular <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 40 mg for large joints and 20 mg for small joints. (See  <a class="medical medical_review" href="/z/d/html/7985.html" rel="external">"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?", section on 'Use of glucocorticoid injections'</a>.)</p><p class="headingAnchor" id="H3896748875"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Patients require monitoring at regular intervals to assess the response to therapy for the psoriatic arthritis (PsA) and related morbidities and to adjust therapy based upon treatment response and adverse medication effects. Patients should be monitored more closely when new medications are being initiated, depending upon the expected response time.</p><p>We monitor patients at three-month intervals when the disease is more active or when treatments are changed. Stable patients may be monitored at six-month intervals. Depending upon the medication, laboratory monitoring may be required more often, sometimes at monthly intervals  (<a class="graphic graphic_table graphicRef142892" href="/z/d/graphic/142892.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease activity</strong> – Disease activity should be assessed by use of joint counts for detection of painful and swollen joints.</p><p></p><p class="bulletIndent1">In addition, the number of areas affected by enthesitis should be assessed, with particular attention, at a minimum, to the Achilles tendon insertions and the plantar fascia in each foot, as well as the epicondyles, since these areas have been shown to be most commonly affected [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">An identification and a count of the number of digits affected by dactylitis should be made. Dactylitis is more common in toes than in fingers and may be missed if feet are not examined.</p><p></p><p class="bulletIndent1">Other measures created for use in rheumatoid arthritis, such as the RAPID3 (a modification of the Routine Assessment of Patient Index Data) and the DAS28-CRP (Disease Activity Score using a 28 joint count and C-reactive protein), may be helpful, but they only reflect peripheral arthritis. Active PsA may still be present in patients with a good response based upon these measures; thus, they cannot be used alone to determine when to stop escalation of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging and joint injury</strong> – We use plain-film radiography of clinically involved peripheral joints, sacroiliac joints, and the spine to assess the extent of disease and to track disease progression. We obtain radiographs at these sites every two years, or more frequently if there is clinical evidence of disease progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Laboratory testing depends primarily upon the specific therapeutic agents being used  (<a class="graphic graphic_table graphicRef142892" href="/z/d/graphic/142892.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Acute phase measures (eg, the sedimentation rate and CRP) should be included in the initial assessment, in part because of their prognostic implications. (See <a class="local">'Risk factors for progressive joint damage'</a> below.)</p><p></p><p>In the treat-to-target approach, treatment is adjusted at frequent and defined intervals (eg, every three months) if the target is not met (see <a class="local">'Treat-to-target approach'</a> above). The benefits of this strategy were supported by a multicenter open-label trial in the United Kingdom involving 206 patients with recent-onset active PsA who had not previously received DMARD therapy [<a href="#rid11">11</a>]. Patients who were assigned to tight control (every four week visits with prespecified treatment escalation if the target was not met) were significantly more likely to achieve American College of Rheumatology (ACR) composite criteria for at least 20 percent improvement (an ACR20 response) at 48 weeks, compared with patients receiving standard care as defined by their treating clinician (ACR20 in 44 versus 18 percent; odds ratio [OR] 1.91, 95% CI 1.03-3.55). It is important to note, however, that combination therapies prescribed in this trial for some patients, including <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and combined treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, are not commonly prescribed in the United States for PsA. While patients were evaluated every four weeks in this study, this frequency may not be feasible or necessary in clinical practices.</p><p class="headingAnchor" id="H803159"><span class="h1">ROLE OF SURGERY</span><span class="headingEndMark"> — </span>We consider joint replacement surgery for patients with severe joint destruction that impacts their daily activities and is unlikely to improve with immunosuppression. We also consider surgical repair of tendons in the hands and the Achilles in patients with significant pain and dysfunction.</p><p>When a patient may have a partial tendon rupture in addition to tendonitis, ultrasound and/or MRI imaging are recommended to establish the correct diagnosis. Such patients should be referred to a plastic or orthopedic surgeon if the patient is at imminent risk of tendon rupture.</p><p>In general, surgical outcomes among psoriatic arthritis (PsA) patients are comparable to the outcomes in patients with osteoarthritis [<a href="#rid47">47</a>]. However, the long-term outcomes of joint replacement surgery in patients with PsA have not been well studied [<a href="#rid47">47-49</a>]. Total hip joint replacement and small joint arthroplasty may result in excess bone proliferation or periarticular fibrosis that impair long-term mobility [<a href="#rid50">50</a>].</p><p>The joint replacement procedures available to patients with PsA are similar to the procedures available to patients with end-stage rheumatoid arthritis. (See  <a class="medical medical_review" href="/z/d/html/7478.html" rel="external">"Surgical management of end-stage rheumatoid arthritis", section on 'Surgical options'</a>.)</p><p class="headingAnchor" id="H72442856"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2348348901"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>Psoriatic arthritis (PsA) was once considered a mild disease for which clinicians were reluctant to use disease-modifying antirheumatic drugs (DMARDs). However, it has since become clear that the disease is more severe than previously described [<a href="#rid51">51</a>]. Two years after disease onset in an early disease cohort, 47 percent of patients had radiographic erosions in the hands and feet, and 56 percent were taking DMARDs. In another prospective cohort study of 100 patients with PsA, the majority of patients showed progression in the number of joints involved, and 68 percent manifested radiographic progression at five years [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/7784.html" rel="external">"Clinical manifestations and diagnosis of psoriatic arthritis"</a>.)</p><p>Some clinical and genetic risk factors for disease progression have been identified. Such information can help to prospectively identify patients who will benefit from aggressive early treatment. Severe disease may adversely affect survival.</p><p>Complete relief of joint tenderness and swelling may occur in a substantial minority of treated patients. As an example, in a study of 391 patients, 69 (18 percent) achieved remission, and nearly one-half remained free of active joint disease without continued use of medication [<a href="#rid54">54</a>]. Periods of remission lasted an average of approximately 2.5 years. However, the majority experienced at least one relapse after a mean duration of remission of 2.6 years.</p><p>Predictors of achieving remission include [<a href="#rid54">54,55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Mild disease</p><p class="bulletIndent1"><span class="glyph">●</span>Less disability at presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Low body mass index (BMI)</p><p class="bulletIndent1"><span class="glyph">●</span>Use of biologic agents</p><p></p><p>The Madrid Sonographic Enthesis Index (MASEI) was significantly more severe in association with human leukocyte antigen B27 (HLA-B27) in the presence of longer disease duration in a PsA cohort [<a href="#rid56">56</a>]. In the same cohort, a high MASEI was associated with peripheral joint damage (higher modified Steinbrocker Score, ankyloses, arthritis mutilans, and periostitis) and axial damage (modified Stoke Ankylosing Spondylitis Spine Score and sacroiliitis) [<a href="#rid57">57</a>] after adjustment for age, sex, PsA duration, BMI, smoking, and current use of DMARDs and biologics.</p><p>Females with PsA have worse quality of life, higher disease activity, and shorter biologic drug survival than males with PsA [<a href="#rid58">58,59</a>].</p><p class="headingAnchor" id="H72442968"><span class="h2">Risk factors for progressive joint damage</span><span class="headingEndMark"> — </span>PsA patients with the following risk factors for progressive joint damage may merit more aggressive therapy and closer follow-up:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased numbers of actively inflamed joints</strong> – Polyarticular rather than oligoarticular presentation, higher tender and swollen joint counts, a high number of joint effusions, and the damage present predict progression of clinical and radiologic damage [<a href="#rid60">60-64</a>]. Of 129 patients with PsA identified in an early arthritis clinic, the number of patients with at least one erosion in the hands or feet increased from 27 percent at baseline to 47 percent by the two-year follow-up [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated acute phase reactants</strong> – A low erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) generally indicates that the patient is at low risk for progression [<a href="#rid63">63</a>]. In addition, each mm/hour increase in the ESR is associated with a 2 percent increased risk of progression of both clinical and radiologic damage [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of previous medication trials</strong> – A high level of past medication use (particularly glucocorticoids) predicts progression of clinical damage [<a href="#rid60">60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint damage</strong> – The importance of aggressive treatment of inflammatory joint disease is supported by the finding that inflammation in a particular joint predicts progression of damage in that joint [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-citrullinated peptide antibodies</strong> – The presence of anti-citrullinated peptide antibodies (ACPA) is associated with an increased prevalence of polyarthritis and of erosive joint disease in a cross-sectional study of patients with PsA [<a href="#rid67">67</a>]. In one study of 588 patients with PsA, ACPA were detected in 7 percent [<a href="#rid68">68</a>]. It is not known whether these antibodies are present in early disease (and could help predict disease course) or if they develop later in the illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated MASEI sonographic enthesitis score</strong> – As above.</p><p></p><p>HLA typing provides important predictive information, but we do not perform such testing routinely in our practice. However, with further developments, HLA testing may have greater potential to provide clinically useful prognostic information. In univariate analysis, patients who are HLA-B27-, -B39-, or -DQw3-positive are at a higher risk for progression of clinical damage; these antigens are stronger prognostic factors than the clinical variables [<a href="#rid69">69</a>]. The presence of HLA-DR7 appears to be "protective," predicting less progression. The best multivariate model identified HLA-B27 when -DR7 is present, and -DQw3 when -DR7 is not present, as predicting disease progression. HLA-B39 was associated with progression in early disease [<a href="#rid69">69</a>]. HLA-B22 is protective when all HLA antigens are added to the model [<a href="#rid70">70</a>].</p><p>Haplotypes HLA-B27:05:02/C-02:02:02 and HLA-B08:01:01/C-07:01:01 were associated with the highest tertile of a PsA severity propensity score based on the presence of enthesitis, dactylitis, sacroiliitis, joint deformity, joint fusion, erosion, and osteolysis [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H72443475"><span class="h2">Cardiovascular disease and mortality</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – Patients with PsA may be at increased risk for cardiovascular disease and/or death. In one study, patients with either psoriasis or PsA had a significant increased risk of myocardial infarction, angina, and hypertension versus the general population [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – Conflicting data exist concerning the association between PsA and increased mortality [<a href="#rid73">73-76</a>]. Survival appears to have improved since the late 1970s and early 1980s, possibly related to more effective therapeutic approaches [<a href="#rid73">73</a>]. A single-center study of 453 patients with PsA in the United Kingdom between 1985 and 2007 found no increase in mortality risk compared with the general population [<a href="#rid77">77</a>]. A meta-analysis of 12 studies of PsA demonstrated a slightly increased mortality among female (relative risk [RR] 1.19) but not in male (RR 1.02) patients [<a href="#rid78">78</a>]. In this meta-analysis, PsA patients had a higher risk of mortality from cardiovascular (RR 1.21), respiratory (RR 3.37) and infectious (RR 2.43) causes but not malignancy (RR 1.01).</p><p></p><p class="headingAnchor" id="H3026196833"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112598.html" rel="external">"Society guideline links: Psoriatic arthritis in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118770.html" rel="external">"Society guideline links: Spondyloarthritis"</a>.)</p><p class="headingAnchor" id="H38"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86739.html" rel="external">"Patient education: Psoriatic arthritis in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/515.html" rel="external">"Patient education: Psoriatic arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20469265"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment recommendations</strong> – Treatment of psoriatic arthritis (PsA) should be started early in disease and be coordinated among a rheumatologist, a primary care clinician, and other specialists (eg, a dermatologist). Differences in response to individual therapies between the skin and joints, and among different musculoskeletal manifestations, are commonly observed.</p><p></p><p class="bulletIndent1">Treatment is guided initially by an assessment of disease severity, including the degree of disease activity, damage, and impact on the patient for each clinical domain. A treat-to-target approach should be employed, with a target of remission/inactive disease or low/minimal disease activity. Attention to the most severely and impactful involved region should guide therapy  (<a class="graphic graphic_figure graphicRef142062" href="/z/d/graphic/142062.html" rel="external">figure 1</a>). (See <a class="local">'Pretreatment recommendations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of peripheral arthritis</strong> – The management of the peripheral arthritis of PsA is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/141133.html" rel="external">"Treatment of peripheral psoriatic arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of axial disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild axial disease</strong> – In patients with mild axial disease (eg, patients with inflammatory back pain that does not interfere with function), we suggest nonsteroidal antiinflammatory drugs (NSAIDs) in antiinflammatory-dose regimens  (<a class="graphic graphic_table graphicRef70067" href="/z/d/graphic/70067.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Suggested regimens include <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> 375 to 500 mg twice daily, <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> 100 to 150 mg daily in divided doses, or <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> 200 mg twice daily. (See <a class="local">'Mild axial symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe axial disease</strong> – In patients with axial symptoms that do not respond adequately to treatment with NSAIDs, we recommend a tumor necrosis factor (TNF) or interleukin 17 (IL-17) inhibitor (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Nonbiologic disease-modifying antirheumatic drugs (DMARDs) appear to be ineffective in axial spondylitis, and therefore are not used for axial disease in PsA.</p><p></p><p class="bulletIndent2">The choice of agent and dosing are the same as those used for peripheral arthritis, except that IL-12/23 inhibitors (eg, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>) are not recommended due to lack of consistent evidence for benefit in axial spondyloarthritis  (<a class="graphic graphic_table graphicRef143868" href="/z/d/graphic/143868.html" rel="external">table 2</a>). (See <a class="local">'Moderate to severe axial disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Axial disease unresponsive to initial tumor necrosis factor inhibitor</strong> – In patients with axial symptoms that do not respond adequately to initial therapy with a TNF inhibitor, we switch to a second TNF inhibitor or an alternative agent such as <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, or a Janus kinase (JAK)/signal transducer and activator of transcription (STAT) inhibitor. Other options may include <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> and <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>. (See <a class="local">'Axial disease resistant to initial tumor necrosis factor inhibitor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Axial disease unresponsive to multiple agents</strong> – In patients with axial symptoms that do not respond adequately to therapy with TNF inhibition or <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, we switch to <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>.</p><p></p><p class="bulletIndent2">For patients who do not respond adequately to therapy with several agents, including JAK inhibition and multiple TNF and IL-17 inhibitors, we would consider <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, although the data supporting the use of this drug for axial PsA are poor. (See <a class="local">'Axial disease resistant to multiple agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of enthesitis</strong> – In patients with enthesitis, a response is often seen with medications used for other manifestations of PsA.</p><p></p><p class="bulletIndent1">In patients with enthesitis causing functional impairment who do not respond to NSAIDs and local therapy, we suggest using a biologic agent, initially a TNF inhibitor  (<a class="graphic graphic_table graphicRef143868" href="/z/d/graphic/143868.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Enthesitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of dactylitis</strong> – In patients with dactylitis who do not respond to NSAIDs, we treat with a conventional DMARD (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 15 to 25 mg once weekly), and if that is inadequate, we use a biologic agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment with a biologic agent is likely to be necessary in patients with severe dactylitis that affects multiple digits. (See <a class="local">'Dactylitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for glucocorticoids</strong> – Use of oral glucocorticoids in patients with PsA should be avoided, and when required (eg, for severe flares), the dose should be the minimum needed. It is important to taper the glucocorticoids with close observation for the development of erythroderma or pustular psoriasis.</p><p></p><p class="bulletIndent1">Intraarticular glucocorticoids are sometimes used, and care should be taken in patients who require such injections to avoid injection through psoriatic plaques. (See <a class="local">'Limited role of glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease monitoring</strong> – Clinical monitoring of disease should include joint counts that assess both the upper and lower extremities as well as the number of areas involved by enthesitis and by dactylitis.</p><p></p><p class="bulletIndent1">Plain film radiography of clinically involved peripheral joints, the sacroiliac joints, and the spine are also used to assess the extent and progression of disease at these sites.</p><p></p><p class="bulletIndent1">Laboratory and clinical monitoring is also advised for certain medication regimens  (<a class="graphic graphic_table graphicRef142892" href="/z/d/graphic/142892.html" rel="external">table 4</a>). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Joint replacement surgery may be necessary for patients with severe joint destruction. However, long-term outcomes of joint replacement surgery in patients with PsA have not been well described (See <a class="local">'Role of surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – PsA has variable disease expression; a significant proportion of patients may develop destructive and potentially disabling disease. Factors predicting a poor prognosis include a higher number of actively inflamed joints, an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), failure of previous medication trials, the presence of joint damage, loss of function, and diminished quality of life. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2655319989"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Christopher Ritchlin, MD, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bruce IN, Gladman DD. Psoriatic arthritis: recognition and management. BioDrugs 1998; 9:271.</a></li><li><a class="nounderline abstract_t">Cuéllar ML, Citera G, Espinoza LR. Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8:483.</a></li><li><a class="nounderline abstract_t">Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015; 74:1045.</a></li><li><a class="nounderline abstract_t">Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011; 70:2152.</a></li><li><a class="nounderline abstract_t">Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010; 69:48.</a></li><li><a class="nounderline abstract_t">Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73:6.</a></li><li><a class="nounderline abstract_t">Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018; 77:3.</a></li><li><a class="nounderline abstract_t">Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013; 14:101.</a></li><li><a class="nounderline abstract_t">Coates LC. Treating to target in psoriatic arthritis. Curr Opin Rheumatol 2015; 27:107.</a></li><li><a class="nounderline abstract_t">Kavanaugh A, van der Heijde D, Beutler A, et al. Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. Arthritis Care Res (Hoboken) 2016; 68:267.</a></li><li><a class="nounderline abstract_t">Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015; 386:2489.</a></li><li><a class="nounderline abstract_t">Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386:316.</a></li><li><a class="nounderline abstract_t">Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 2019; 21:17.</a></li><li><a class="nounderline abstract_t">Klingberg E, Björkman S, Eliasson B, et al. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther 2020; 22:254.</a></li><li><a class="nounderline abstract_t">Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75:499.</a></li><li><a class="nounderline abstract_t">Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68:1387.</a></li><li><a class="nounderline abstract_t">Nash P, Lubrano E, Cauli A, et al. Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol 2014; 41:2286.</a></li><li><a class="nounderline abstract_t">Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18:465.</a></li><li><a class="nounderline abstract_t">Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013; :CD004524.</a></li><li><a class="nounderline abstract_t">Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014; :CD004800.</a></li><li><a class="nounderline abstract_t">Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71:4.</a></li><li><a class="nounderline abstract_t">Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68:1060.</a></li><li><a class="nounderline abstract_t">Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021; 80:582.</a></li><li><a class="nounderline abstract_t">Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015; 373:2534.</a></li><li><a class="nounderline abstract_t">Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2021; 80:1004.</a></li><li><a class="nounderline abstract_t">van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76:1340.</a></li><li><a class="nounderline abstract_t">Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022; 400:369.</a></li><li><a class="nounderline abstract_t">van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 2022; 81:1515.</a></li><li><a class="nounderline abstract_t">van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394:2108.</a></li><li><a class="nounderline abstract_t">Deodhar A, Gensler LS, Sieper J, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol 2019; 71:258.</a></li><li><a class="nounderline abstract_t">Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open 2020; 6.</a></li><li><a class="nounderline abstract_t">Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials 2022; 23:743.</a></li><li><a class="nounderline abstract_t">Panagiotopoulos A, Koutsianas C, Kougkas N, et al. Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease. Rheumatol Int 2023; 43:969.</a></li><li><a class="nounderline abstract_t">Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol 2021; 3:e715.</a></li><li><a class="nounderline abstract_t">Eder L, Mathew AJ, Carron P, et al. Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol 2023; 50:258.</a></li><li><a class="nounderline abstract_t">Palominos PE, Fernández-Ávila DG, Coates LC, et al. Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol 2023; 50:265.</a></li><li><a class="nounderline abstract_t">Mathew AJ, Sutton M, Pereira D, et al. Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. J Rheumatol 2022; 49:1020.</a></li><li><a class="nounderline abstract_t">Orbai AM, Weitz J, Siegel EL, et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol 2014; 41:2290.</a></li><li><a class="nounderline abstract_t">McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med 2021; 384:1227.</a></li><li><a class="nounderline abstract_t">Gladman DD, Orbai AM, Klitz U, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther 2019; 21:38.</a></li><li><a class="nounderline abstract_t">Mease PJ, Gladman DD, Collier DH, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol 2019; 71:1112.</a></li><li><a class="nounderline abstract_t">Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open 2018; 4:e000669.</a></li><li><a class="nounderline abstract_t">Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis 2020; 79:490.</a></li><li><a class="nounderline abstract_t">Rose S, Toloza S, Bautista-Molano W, et al. Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol 2014; 41:2295.</a></li><li><a class="nounderline abstract_t">Vincken NLA, Balak DMW, Knulst AC, et al. Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Rheumatology (Oxford) 2022; 61:4232.</a></li><li><a class="nounderline abstract_t">Polachek A, Li S, Chandran V, Gladman D. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: Incidence, prevalence, characteristics and outcome. Arthritis Care Res (Hoboken) 2016.</a></li><li><a class="nounderline abstract_t">Zangger P, Esufali ZH, Gladman DD, Bogoch ER. Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol 2000; 27:967.</a></li><li><a class="nounderline abstract_t">Zangger P, Gladman DD, Bogoch ER. Musculoskeletal surgery in psoriatic arthritis. J Rheumatol 1998; 25:725.</a></li><li><a class="nounderline abstract_t">Lambert JR, Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil 1979; 18:35.</a></li><li><a class="nounderline abstract_t">Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9:75.</a></li><li><a class="nounderline abstract_t">Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med 1987; 62:127.</a></li><li><a class="nounderline abstract_t">McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42:778.</a></li><li><a class="nounderline abstract_t">Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63:382.</a></li><li><a class="nounderline abstract_t">Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001; 28:1045.</a></li><li><a class="nounderline abstract_t">Alharbi S, Ye JY, Lee KA, et al. Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum 2020; 50:1494.</a></li><li><a class="nounderline abstract_t">Polachek A, Cook R, Chandran V, et al. The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. Arthritis Rheumatol 2018; 70:756.</a></li><li><a class="nounderline abstract_t">Polachek A, Cook R, Chandran V, et al. Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Res Ther 2019; 21:20.</a></li><li><a class="nounderline abstract_t">Tarannum S, Leung YY, Johnson SR, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol 2022; 18:513.</a></li><li><a class="nounderline abstract_t">Orbai AM, Perin J, Gorlier C, et al. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. Arthritis Care Res (Hoboken) 2020; 72:1772.</a></li><li><a class="nounderline abstract_t">Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 Suppl 2:ii14.</a></li><li><a class="nounderline abstract_t">Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26:2409.</a></li><li><a class="nounderline abstract_t">Queiro-Silva R, Torre-Alonso JC, Tinturé-Eguren T, López-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62:68.</a></li><li><a class="nounderline abstract_t">Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22:675.</a></li><li><a class="nounderline abstract_t">Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007; 66:370.</a></li><li><a class="nounderline abstract_t">Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42:1460.</a></li><li><a class="nounderline abstract_t">Cresswell L, Chandran V, Farewell VT, Gladman DD. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011; 70:305.</a></li><li><a class="nounderline abstract_t">Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32:511.</a></li><li><a class="nounderline abstract_t">Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665.</a></li><li><a class="nounderline abstract_t">Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995; 38:845.</a></li><li><a class="nounderline abstract_t">Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25:730.</a></li><li><a class="nounderline abstract_t">Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 2016; 75:155.</a></li><li><a class="nounderline abstract_t">Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68:1131.</a></li><li><a class="nounderline abstract_t">Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007; 56:2708.</a></li><li><a class="nounderline abstract_t">Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26:S62.</a></li><li><a class="nounderline abstract_t">Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000; 27:1247.</a></li><li><a class="nounderline abstract_t">Elalouf O, Muntyanu A, Polachek A, et al. Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. Semin Arthritis Rheum 2020; 50:571.</a></li><li><a class="nounderline abstract_t">Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis - a single-center study from the UK. J Rheumatol 2010; 37:2141.</a></li><li><a class="nounderline abstract_t">Chaudhary H, Bohra N, Syed K, et al. All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2023; 75:1052.</a></li></ol></div><div id="topicVersionRevision">Topic 7793 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18020565" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psoriatic arthritis: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076399" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525911" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21914627" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147615" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749611" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28684559" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517506" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25603035" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treating to target in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25779603" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433318" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081280" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635024" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33092646" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644232" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18952643" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment recommendations for psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362712" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Updated guidelines for the management of axial disease in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35761070" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450553" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Methotrexate for ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427435" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sulfasalazine for ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21953336" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749174" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33334727" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26699169" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33906853" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28130206" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35908570" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35788492" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31732180" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30225992" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209721" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36064592" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36840819" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38287608" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36319005" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36319013" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35649547" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362713" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789011" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30696483" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30747501" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30018799" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32193187" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362714" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comprehensive treatment of dactylitis in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35285486" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998023" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: Incidence, prevalence, characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782824" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558176" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Musculoskeletal surgery in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/424665" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Surgery in patients with psoriasis and arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/392764" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3659255" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Psoriatic arthritis (PSA)--an analysis of 220 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730539" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279995" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factorαtherapy: results from the nationwide Danish DANBIO registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11361187" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Remission in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145969" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Remission in psoriatic arthritis: Definition and predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29361203" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30642391" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927578" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sex- and gender-related differences in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31609525" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708927" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Psoriatic arthritis: epidemiology, clinical features, course, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555902" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Progression in psoriatic arthritis: role of time varying clinical indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480674" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791162" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916855" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Predictors for radiological damage in psoriatic arthritis: results from a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523223" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980703" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742445" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antibodies to cyclic citrullinated peptides in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16871531" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Classification criteria for psoriatic arthritis: development of new criteria from a large international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7779129" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558177" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HLA markers and progression in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261574" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18697777" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cardiovascular morbidity in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665458" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Improved survival in psoriatic arthritis with calendar time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026145" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mortality in psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10813295" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32454305" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mortality in psoriatic arthritis: Risk, causes of death, predictors for death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682670" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mortality in psoriatic arthritis - a single-center study from the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34788902" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
